[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.241.199. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1992

Ultraviolet-B Phototherapy for Early-Stage Cutaneous T-cell Lymphoma

Author Affiliations

From the Department of Dermatology (Drs Ramsay, Lish, Yalowitz, and Soter) and the Lymphoma (Dr Ramsay) and Photomedicine (Dr Soter) Sections of the Charles C. Harris Skin and Cancer Pavilion, New York (NY) University School of Medicine.

Arch Dermatol. 1992;128(7):931-933. doi:10.1001/archderm.1992.01680170063007
Abstract

• Background and Design.—  Cutaneous T-cell lymphoma (CTCL) is a slowly advancing disease that initially presents in the skin and may later progress to involve the lymph nodes and viscera. Since CTCL most often presents on non-sunlight-exposed regions of the body, a possible protective role for UVB irradiation has been suggested. Recent observations have also found that UVB irradiation serves an immunoregulatory role. Given that limited data are available regarding the use of UVB phototherapy in treating CTCL, a retrospective nonrandomized study of 37 nonconsecutive patients with early CTCL was performed to assess the efficacy of UVB phototherapy in the treatment of CTCL.

Results.—  Twenty-five (71%) of the 35 patients treated with UVB phototherapy (two were unavailable for follow-up) achieved a total clinical remission. Median time to remission was 5 months, and median duration of the remission was 22 months. Twenty-five (83%) of 30 patients with disease limited to patches achieved remission, whereas none of the patients with plaque-level disease achieved a remission. Of the 25 patients who achieved complete remission, five (20%) had a recurrence of CTCL.

Conclusions.—  Phototherapy with UVB appears to be effective in patients with early patch-stage CTCL.(Arch Dermatol. 1992;128:931-933)

×